Anti-cd73 antibodies and uses thereof
AssigneeIncyte Corporation
InventorsHoracio G. Nastri, Shaun M. Stewart, Juan Carlos Almagro, Jing Zhou, Rebecca A. Buonpane
Life of this patent
Estimating the term…
Abstract
Anti-CD73 antibodies are disclosed. Also disclosed are related nucleic acids, vectors, cells, and pharmaceutical compositions. Methods of treating cancer with the anti-CD73 antibodies are also disclosed.
Claims39
An antibody that binds to human CD73, wherein the antibody comprises a variable heavy (VH) domain comprising VH complementarity determining region (CDR)1, VH CDR2, and VH CDR3, wherein:
- the VH CDR1 comprises the amino acid sequence GYTFTSYG (SEQ ID NO:1);
- the VH CDR2 comprises the amino acid sequence IYPGSGNT (SEQ ID NO:2);
- and
- the VH CDR3 comprises the amino acid sequence ARYDYLGSSYGFDY (SEQ ID NO:3);
- and
- wherein the antibody comprises a variable light (VL) domain comprising VL CDR1, VL CDR2, and VL CDR3, wherein:
- the VL CDR1 comprises the amino acid sequence QDVSTA (SEQ ID NO:4);
- the VL CDR2 comprises the amino acid sequence SAS (SEQ ID NO:5);
- and
- the VL CDR3 comprises the amino acid sequence QQHYNTPYT (SEQ ID NO:6).
An antibody that binds to human CD73, wherein the antibody binds to human CD73 at an epitope within amino acids 40-53 of SEQ ID NO:70.
An antibody that binds to human CD73 and competes for binding to human CD73 with an antibody that has a heavy chain comprising the amino acid sequence of SEQ ID NO:24 and a light chain comprising the amino acid sequence of SEQ ID NO:25.
An isolated cell:
- (a) comprising a nucleic acid or nucleic acids encoding an antibody that binds to human CD73;
- (b) comprising an expression vector or expression vectors comprising a nucleic acid or nucleic acids encoding an antibody that binds to human CD73;
- (c) comprising a first expression vector comprising a first nucleic acid encoding a first polypeptide comprising a variable heavy (VH) domain of an antibody that binds to human CD73 operably linked to a promoter, and a second expression vector comprising a second nucleic acid encoding a second polypeptide comprising a variable light (VL) domain of the antibody that binds to human CD73 operably linked to a promoter;
- or
- (d) that produces an antibody that binds to human CD73;
- wherein the antibody that binds to human CD73 comprises a VH domain comprising VH complementarity determining region (CDR)1, VH CDR2, and VH CDR3, wherein:
- the VH CDR1 comprises the amino acid sequence GYTFTSYG (SEQ ID NO:1);
- the VH CDR2 comprises the amino acid sequence IYPGSGNT (SEQ ID NO:2);
- and
- the VH CDR3 comprises the amino acid sequence ARYDYLGSSYGFDY (SEQ ID NO:3);
- and
- wherein the antibody comprises a VL domain comprising VL CDR1, VL CDR2, and VL CDR3, wherein:
- the VL CDR1 comprises the amino acid sequence QDVSTA (SEQ ID NO:4);
- the VL CDR2 comprises the amino acid sequence SAS (SEQ ID NO:5);
- and
- the VL CDR3 comprises the amino acid sequence QQHYNTPYT (SEQ ID NO:6).
(canceled)
(canceled)
(canceled)
(canceled)
An antibody that binds to human CD73, wherein the antibody comprises a variable heavy (VH) domain comprising VH complementarity determining region (CDR)1, VH CDR2, and VH CDR3, wherein:
- the VH CDR1 comprises the amino acid sequence GFTFSSYD (SEQ ID NO:34);
- the VH CDR2 comprises the amino acid sequence MSYDGSNK (SEQ ID NO:35) or MSYEGSNK (SEQ ID NO:40);
- and
- the VH CDR3 comprises the amino acid sequence ATEIAAKGDY (SEQ ID NO:36);
- and
- wherein the antibody comprises a variable light (VL) domain comprising VL CDR1, VL CDR2, and VL CDR3, wherein:
- the VL CDR1 comprises the amino acid sequence QGISNY (SEQ ID NO:37);
- the VL CDR2 comprises the amino acid sequence AAS (SEQ ID NO:38);
- and
- the VL CDR3 comprises the amino acid sequence QQSYSTPH (SEQ ID NO:39).
-39. (canceled)
An antibody that binds to human CD73, wherein the antibody binds to human CD73 at an epitope within amino acids 386-399 and 470-489 of SEQ ID NO:70.
An antibody that binds to human CD73 and competes for binding to human CD73 with an antibody that has a heavy chain comprising the amino acid sequence of SEQ ID NO:30 and a light chain comprising the amino acid sequence of SEQ ID NO:31.
An antibody that binds to human CD73 and competes for binding to human CD73 with an antibody that has a heavy chain comprising the amino acid sequence of SEQ ID NO:33 and a light chain comprising the amino acid sequence of SEQ ID NO:31.
(canceled)
(canceled)
An isolated cell:
- (a) comprising a nucleic acid or nucleic acids encoding an antibody that binds to human CD73;
- (b) comprising an expression vector or expression vectors comprising a nucleic acid or nucleic acids encoding an antibody that binds to human CD73;
- (c) comprising a first expression vector comprising a first nucleic acid encoding a first polypeptide comprising a variable heavy (VH) domain of an antibody that binds to human CD73 operably linked to a promoter, and a second expression vector comprising a second nucleic acid encoding a second polypeptide comprising a variable light (VL) domain of the antibody that binds to human CD73 operably linked to a promoter;
- or
- (d) that produces an antibody that binds to human CD73;
- wherein the antibody that binds to human CD73 comprises a VH domain comprising VH complementarity determining region (CDR)1, VH CDR2, and VH CDR3, wherein:
- the VH CDR1 comprises the amino acid sequence GFTFSSYD (SEQ ID NO:34);
- the VH CDR2 comprises the amino acid sequence MSYDGSNK (SEQ ID NO:35) or MSYEGSNK (SEQ ID NO:40);
- and
- the VH CDR3 comprises the amino acid sequence ATEIAAKGDY (SEQ ID NO:36);
- and
- wherein the antibody comprises a VL domain comprising VL CDR1, VL CDR2, and VL CDR3, wherein:
- the VL CDR1 comprises the amino acid sequence QGISNY (SEQ ID NO:37);
- the VL CDR2 comprises the amino acid sequence AAS (SEQ ID NO:38);
- and
- the VL CDR3 comprises the amino acid sequence QQSYSTPH (SEQ ID NO:39).
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.